Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects With Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 13 Nov 2018 Planned End Date changed from 1 Sep 2019 to 11 Feb 2019.
- 13 Nov 2018 Planned primary completion date changed from 1 Sep 2019 to 11 Feb 2019.
- 13 Nov 2018 Status changed from recruiting to active, no longer recruiting.